|Bid||2.7900 x 4000|
|Ask||2.8000 x 4000|
|Day's Range||2.7900 - 2.9700|
|52 Week Range||1.5400 - 3.8800|
|Beta (3Y Monthly)||1.43|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 28, 2017 - Jul 31, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
Agenus (AGEN) delivered earnings and revenue surprises of -15.15% and 192.92%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
LEXINGTON, Mass., Aug. 8, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced today that the FDA has accepted the company's IND filing for AGEN2373, a milestone in its partnership with Gilead Sciences, Inc. This milestone triggers a cash payment of $7.5M. Agenus is eligible to receive additional milestone payments this year and beyond.
- Enrollment of CTLA-4 & PD-1 trials on track; data expected 2H2019 - Second generation CTLA-4 advances in clinic; data expected 2H2019 - Launched commercial readiness with head of commercial on board ...
LEXINGTON, Mass., Aug. 6, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its second quarter 2019 financial results before the market opens on Thursday, August 8, 2019. Agenus executives will host a conference call and webcast at 8:30 a.m. ET the same day. The call will also be webcast and will be accessible from the Company's website at http://investor.agenusbio.com/presentation-webcasts or with this link https://www.webcaster4.com/Webcast/Page/1556/31262.
LEXINGTON, Mass., July 18, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a broad pipeline of novel clinical and preclinical stage checkpoint antibodies, cell therapies and neoantigen vaccines, today announced the appointment of Don Vidic as Vice President, Head of Commercial. "Don has deep expertise in market access and distribution strategies and shares our commitment to disruptive commercial models designed to provide access to all patients who need our products," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus. "We have built a unique ecosystem which has allowed us to innovate with speed and set new records in drug discovery and development. We are on track to submit our first BLA filing for our lead CTLA-4 and PD-1 molecules in 2020.
Agenus (AGEN) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Gilead (GILD) collaborates with Nurix Therapeutics to leverage the proprietary drug discovery platform of the latter to identify novel agents that induce degradation of specified drug targets.
LEXINGTON, Mass. , June 13, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies ...
MARIETTA, Ga., May 30, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or the "Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that the Company's board of directors (the "Board") has adopted a comprehensive plan to refresh the composition of the Board. The plan was developed by the Board in cooperation with one of the Company's largest shareholders, Prescience Point Capital Management LLC ("Prescience Point"), and follows the completion of the Audit Committee's independent investigation into alleged wrongdoing by the prior senior management team and the engagement of BDO USA, LLP as the Company's new independent registered public accounting firm.
Agenus (AGEN) is developing its pipeline candidates and has an array of collaboration contracts to its credit that bodes well for growth.
Agenus (AGEN) delivered earnings and revenue surprises of 140.00% and -4.65%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Lexington, Massachusetts-based company said it had net income of 12 cents per share. The biotechnology company posted revenue of $8.6 million in the period. The company's shares closed at $2.66. A ...
- Gilead partnership yields $150M & first milestone of $7.5M - Exceeding enrollment targets in BLA path CTLA-4 & PD-1 trials - Second generation CTLA-4 in the clinic; combos and data planned in 2019 - ...
NEW YORK, NY / ACCESSWIRE / May 9, 2019 / Agenus, Inc. (NASDAQ: AGEN ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 9, 2019 at 8:30 AM Eastern Time. ...
LEXINGTON, Mass. , May 3, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies ...